Oncology News | pharmaphorum

News

NICE rejects Ipsen’s Cabometyx in thyroid cancer

Ipsen’s Cabometyx should not be used by the NHS for patients with differentiated thyroid cancer who have either not responded to or are ineligible for radioactive iodine t

News

Pressure raises on Illumina as FTC orders it to shed Grail

The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition an

News

Eisai plans ‘patient-proposed’ trial of cancer drug Tazverik

Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treatment availab

News

FDA clears Keytruda/Padcev regimen for bladder cancer

The combination of Merck & Co’s checkpoint inhibitor Keytruda and Seagen/Astellas’ antibody-drug conjugate Padcev has been approved by the FDA as an alternative to che

News

Hutchmed files Takeda-partnered colorectal cancer drug in US

Chinese biotech Hutchmed has completed its rolling marketing application in the US for oral VEGF receptor inhibitor fruquintinib, which was licensed by Takeda for a hefty

News

GSK, Merck in endometrial cancer face-off

GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer

NICE rejects Ipsen’s Cabometyx in thyroid cancer

Pressure raises on Illumina as FTC orders it to shed Grail

Eisai plans ‘patient-proposed’ trial of cancer drug Tazverik

FDA clears Keytruda/Padcev regimen for bladder cancer

Hutchmed files Takeda-partnered colorectal cancer drug in US

GSK, Merck in endometrial cancer face-off

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks